Abstract:Abstract Background Despite the advance in neoadjuvant chemothepray/chemoradiotherapy and favourable outcomes of surgical management in supraclavicular lymph node (SCLN) involvement reported in recent studies, the latest AJCC/UICC TMN classification still regards SCLN metastasis as extra-regional i.e Stage IVB (M1) disease. The role of SCLN dissection and surgical management remain controversial. At National University Hospital of the present study, bilateral supraclavicular lymphadenectomy is routinely performed for resectable thoracic ESCC. The aim of this retrospective cohort study is to investigate the long-term outcome of surgical management in pathological SCLN metastasis and its survival benefit comparing to Stage IIB-IVA diseases. Methods Patients with ESCC who underwent esophagectomy and 3-field lymphadenectomy with curative intent between January 2013 and January 2023 at the single centre were included; cases of salvage esophagectomy post-definitive concurrent chemoradiotherapy, palliative resections, and concurrent head and neck cancers were excluded. Neoadjuvant treatments were considered in cases staged clinically as T2 and/or N1 or greater. Pathological status of lymph nodes was recorded according to JES classification. Demographics and prognostic factors were examined using univariant analysis of overall survival (OS). Patients with SCLN metastases and other LN involvements were compared and OS were analysed using Kaplan-Meier method. Results 544 patients were included. 183 had one or more pathological LN metastasis (pN1:126, pN2 46, and PN3: 11) in which 55 patients had SCLN metastasis. Patients with LN metastasis had poorer prognosis than those without (pN0) with a Hazard Ratio (HR) of 2.68 (95% CI, 1.12-3.40, p<0.01); similar pattern was seen in patients with SCLN metastasis (HR 2.28, p<0.01). The 3-year and 5-year OS of patients with SCLN metastasis was 18.5% and 11.6% respectively whereas those of other LN metastasis was 21.4% and 15.8%; the difference between the groups was not statistically significant (p=0.525) (graph 1). Conclusion Lymph node status (pN) is a well-recognised prognostic factor as reaffirmed, however, within the pN positive cohort, long-term survival of patients with SCLN metastasis, considered as stage IVB (M1), was comparable (p<0.05) to those with other LN metastases. This supports the survival benefit of surgical resection with neoadjuvant therapy in SCLN metastases as following nodal disease treatment algorithm; further evaluation including systemic therapy and lymph node sub-group analysis is being conducted. Whilst randomised controlled trials such as Japanese JCOG2013 provides level I evidence, the present study provides complementary real-world experience for SCLN dissection.

Supraomohyoid neck dissection in the management of oral squamous cell carcinoma: special consideration for skip metastases at level IV or V.

[Application of Supraomohyoid Neck Dissection in Oral Squamous Cell Carcinoma with Clinically N0 Neck].

Supraomohyoid neck dissection and modified radical neck dissection for clinically node-negative oral squamous cell carcinoma: a prospective study of prognosis, complications and quality of life

Preservation of level IIb lymph nodes during supraomohyoid neck dissection for clinically node-negative oral squamous cell carcinoma

Clinical Study on Occult Cervical Lymph Node Metastases in Patients with Oral Squamous Cell Carcinoma

Neck Dissection of Level Ib for the Treatment of Cn0 HPV-negative Oropharyngeal Squamous Cell Carcinoma: Should It Be Safely Omitted?

Selective Neck Dissection in the Management of Tongue Squamous Cell Carcinoma with Clinically Negative Nodes

[Level Choice of the Neck Dissection in Clinical N0 Patients with Supraglottic Cancer].

Functional and Supraomohyoid Neck Dissection in Stage Cn0/n1 Oral Squamous Cell Carcinoma

When to manage level V in head and neck carcinoma?

Assessment of level IIB lymph nodes in oral cancer - Should we spare or care?

555. SUPRACLAVICULAR NODE INVOLVEMENT, A NODAL OR METASTATIC DISEASE? - A 10-YEAR EXPERIENCE IN ESOPHAGEAL CARCINOMA AT A TERTIARY REFERRAL CENTRE

[Surgical Management for Occult Cervical Metastasis of Oral Tongue Squamous Cell Carcinoma].

Application of supraomohyoid neck dissection via retroauricular hairline incision in patients with oral cancer

[Selective Neck Dissection on the Treatment of Neck Metastases in 63 Patients with Squamous Cell Carcinoma of Hypopharynx].

Results of a randomized controlled trial of level IIb preserving neck dissection in clinically node-negative squamous carcinoma of the oral cavity

[The prognosis of neck dissection with sternocleidomastoid muscle preservation and resection in advanced oral squamous cell carcinoma: a retrospective cohort analysis]

Adequacy of Disease Control by Supraomohyoid Neck Dissection in cT1/T2 Tongue Cancer

Necessity of level IV dissection in cN0 hypopharyngeal carcinoma

[Outcome of Neck Dissection for 154 Cn0/cn1 Patients with Squamous Cell Carcinoma of Hypopharynx and Prognostic Analysis].

Elective neck dissection in clinical stage I squamous cell carcinoma of the tongue: Does it improve regional control or survival time?